Moderna stock at USD 198.88 on September 25, 2026, up 2.08 percent
Published on 09/28/2026 at 08:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Ahead of the next regular Nasdaq session, Moderna stock last traded at USD 198.88 at 8:00:01 p.m. UTC on September 25, 2026. The shares were up 2.08 percent from the prior close.
Reference session
The quote is for Moderna, Inc. common stock trading under the primary ticker MRNA on Nasdaq. The September 25 session is the latest dated trading information in the quote data.
Moderna sets out ESMO program
In a September 21, 2026 release, Moderna said three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, had been accepted for presentation at the European Society for Medical Oncology Congress 2026 in Madrid from October 23 through October 27.
The program includes Phase 3 data from the INTerpath-001 study of intismeran autogene plus pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma. The release also listed a Phase I pancreatic cancer study and a Phase 3 study in completely resected high-risk stage I non-small cell lung cancer. Moderna said it will host an investor webcast on October 24 at 7:00 p.m. CEST, or 1:00 p.m. EDT, with a replay archived for at least 30 days. ACCESS Newswire identified Moderna and Merck as joint developers of intismeran autogene.
